Schedule 13D ownership disclosure
EYEGATE PHARMACEUTICALS INC
Security class unavailable · CUSIP: 30233M107
Event date: 2017-12-27
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 500,000
- Percent of class
- 49.9900%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001144204-18-001711
- Form type
- SC 13D
- Filer
- Harvard Apparatus Regenerative Technology, Inc.
- CIK
- CIK 1563665
- Filed
- Jan 10, 2018
- Reporting period
- Dec 27, 2017
- Description
- Schedule 13D beneficial ownership